News

Laurent Pharmaceuticals Receives an Additional up to $3M Award from Cystic Fibrosis Foundation

31 October 2019

Laurent Pharmaceuticals Inc. (the “Company”), today announced that it has reached an agreement to receive an additional funding of up to US$ 3 million...

Read More

Laurent Pharmaceuticals Welcomes New Investors and Announces Scientific Breakthrough with LAU-7b in Cystic Fibrosis

25 October 2018

Laurent Pharmaceuticals Inc., a biopharmaceutical company developing LAU-7b (oral fenretinide) first-in-class pro-resolving drug for Cystic Fibrosis (CF), today announced new financing...

Read More

EVENTS

Laurent Pharmaceuticals presents data with LAU-7b in Idiopathic Pulmonary Fibrosis at the 2024 ATS International Conference, May 17-22, San Diego, CA, USA
read more
Laurent Pharma to participate to BIO International Convention,  June 3-6 2024, San Diego, CA, USA
read more

Laurent Pharma to participate to BIO International Convention, June 5-8, 2023, Boston, MA

read more
Laurent Pharma to participate to BIO International Convention, June 13-16, 2022 – San Diego, CA
read more
Laurent Pharma to participate to BIO-Europe Spring, March 28-31, 2022
read more